Affimed (Nasdaq: AFMD) is a clinical stage biopharmaceutical company which engineers targeted immunotherapies, seeking to improve patient outcomes through the power of innate immunity. Affimed’s fit-for-purpose ROCK® platform allows innate immune engagers to be designed for specific patient populations. We are developing single and combination therapies to treat cancers.
To strengthen our growing Research & Development team in Heidelberg, Germany, we are looking for a full-time
(Reference No. R2011)
The successful candidate will be responsible for the non-clinical development of bispecific antibody drug candidates in oncology from lead nomination to IND submission. In this capacity, the Project Leader Non-Clinical Development will head a Non-Clinical Development Team tasked with executing and coordinating all non-clinical development activities and will be an integral member of an international, cross-functional Program Team overseeing development activities and program strategy.
Professional qualifications, expertise and skills
The successful candidate will have the unique opportunity to take on a leading scientific role in the development of an innovative antibody drug for cancer immunotherapy within a highly motivated, multidisciplinary and collegial team, united in its goal to stop cancer from ever derailing patient’s lives.
For any queries, please contact Susanne Hering (Tel: 06221 6743 675, e-mail: firstname.lastname@example.org).